Enveric Biosciences, Inc.
For the period ended May 15, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 15, 2026 · Filed May 15, 2026
Use the contents to explore the available documents and sections.
ENVB$1.42+1.7%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · EB-003 Development:
EB-003 Development:
| ● | Reported EB-003 BRET receptor engagement assay data, demonstrating dual Gq and β-arrestin signaling at 5-HT2A, pathways that have been linked in peer-reviewed studies to antidepressant and anxiolytic effects |
| ● | Subsequent to the end of the first quarter, highlighted positive results for EB-003 indicating a rapid reduction in conditioned fear response in a validated preclinical model of PTSD, supporting continued development for patient population with significant unmet need |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.